IndiaNifty 5024,080.40▼ -0.04%
IndiaBSE Sensex76,957.27▲ +0.03%
IndiaNifty Bank58,024.95▲ +0.92%
IndiaNifty IT31,191.45▼ -0.29%
IndiaNifty Auto28,841.50▲ 0.00%
IndiaNifty Pharma27,188.45▲ +0.73%
IndiaNifty FMCG46,025.55▲ 0.00%
USS&P 5007,686.14▼ -0.58%
USDow Jones53,185.90▼ -0.72%
USNASDAQ26,370.89▼ -0.12%
UKFTSE 10010,816.30▲ +0.22%
JapanNikkei 22566,254.44▼ -0.23%
Hong KongHang Seng25,566.99▼ -0.07%
GermanyDAX26,258.11▼ -1.17%
FranceCAC 408,334.50▼ -0.79%
AustraliaASX 2009,076.00▲ +0.42%
IndiaNifty 5024,080.40▼ -0.04%
IndiaBSE Sensex76,957.27▲ +0.03%
IndiaNifty Bank58,024.95▲ +0.92%
IndiaNifty IT31,191.45▼ -0.29%
IndiaNifty Auto28,841.50▲ 0.00%
IndiaNifty Pharma27,188.45▲ +0.73%
IndiaNifty FMCG46,025.55▲ 0.00%
USS&P 5007,686.14▼ -0.58%
USDow Jones53,185.90▼ -0.72%
USNASDAQ26,370.89▼ -0.12%
UKFTSE 10010,816.30▲ +0.22%
JapanNikkei 22566,254.44▼ -0.23%
Hong KongHang Seng25,566.99▼ -0.07%
GermanyDAX26,258.11▼ -1.17%
FranceCAC 408,334.50▼ -0.79%
AustraliaASX 2009,076.00▲ +0.42%
Invest and Educate
NYQ · USD

Pfizer Inc.

PFE
28.46
▲ 0.50 (+1.79%)
Price Chart
6MO · Daily
2026-03-062026-04-062026-05-042026-06-022026-07-012026-07-302026-08-3123.6725.6727.6728.57
Key Ratios & Fundamentals
Market Cap
161.3B
P/E (TTM)
37.73
Fwd P/E
9.77
P/B
1.89
P/S
2.53
Book Value
14.95
EPS (TTM)
0.75
Fwd EPS
2.90
Div Yield
+6.02%
Beta
0.28
ROE
+5.01%
ROA
+5.78%
D/E
74.25
Current Ratio
1.27
Profit Margin
+6.80%
Op Margin
+27.88%
52W High
28.75
52W Low
23.58
50D Avg
25.49
200D Avg
26.05
Avg Volume
42.3M
Shares Out
5.7B
Sector
Healthcare
Industry
Drug Manufacturers - General
About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SWOT Analysis
Auto-derived from fundamentals
Strengths
  • Superior operating margin of 27.9% — strong operational leverage
  • Attractive dividend yield of 6.02% — steady income component
  • Low beta of 0.28 — defensive characteristics
  • Large-cap scale — index inclusion, institutional coverage, deep liquidity
Weaknesses
  • Modest ROE of 5.0% — capital efficiency lags peers
Opportunities
  • Forward P/E of 9.8x is below trailing — market expects earnings growth
  • Positioned in Healthcare — defensive sector, aligned with respective macro cycles
Threats
  • High PEG of 2.77 — growth may already be priced in
  • Trading near 52-week high (91% of range) — limited upside before pullback
Latest News · Pfizer Inc.
10 stories
Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation
Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liabili
Simply Wall St.·33m ago
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Zacks·5h ago
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
24/7 Wall St.·6h ago
Is Pfizer Stock Underperforming the S&P 500?
PFE has underperformed the broader market over the past year, while analysts remain moderately optimistic about its future prospects.
Barchart·9h ago
Did A Product Swap Fuel JNJ Stock’s 54% Surge?
The signs were not in the headline growth rate but in which two products were trading places.
Trefis·3d ago
Can Merck Stock Outrun Its Pipeline?
Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.
Trefis·3d ago
Pfizer's Updated COVID Shot Ships Into a Smaller Market
The XFG-adapted vaccine targets older and high-risk patients, with deliveries to pharmacies and clinics beginning immediately.
GuruFocus.com·3d ago
BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical
MT Newswires·3d ago
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.
24/7 Wall St.·3d ago
2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
StockStory·3d ago
Invest & Educate · Data: Yahoo Finance · News: ET · Mint · Moneycontrol
PrivacyTermsEducational use only. Not investment advice.